All In Biotech

Drug Trial Radar · NCT04020341

A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,531 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,531

Actual

Start

Oct 17, 2019

Primary completion

Nov 30, 2022

Study completion Nov 30, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

Conditions

  • Urinary Tract Infections

Interventions

  • GepotidacinDrug

    Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.

  • Placebo matching nitrofurantoinDrug

    Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.

  • NitrofurantoinDrug

    Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.

  • Placebo matching gepotidacinDrug

    Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)Time frame: TOC visit (Days 9 to 16)
  2. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S PopulationTime frame: TOC visit (Days 9 to 16)

Locations

103 sites in 12 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Chula Vista, California

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    Lomita, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Northridge, California

  • GSK Investigational Site

    Northridge, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami Springs, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Pompano Beach, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Columbus, Georgia

  • GSK Investigational Site

    Fayetteville, Georgia

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Shreveport, Louisiana

  • GSK Investigational Site

    Watertown, Massachusetts

  • GSK Investigational Site

    Dearborn Heights, Michigan

  • GSK Investigational Site

    Norfolk, Nebraska

  • GSK Investigational Site

    East Brunswick, New Jersey

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Endwell, New York

  • GSK Investigational Site

    Fayetteville, North Carolina

  • GSK Investigational Site

    Scottdale, Pennsylvania

  • GSK Investigational Site

    Smithfield, Pennsylvania

  • GSK Investigational Site

    Clarksville, Tennessee

  • GSK Investigational Site

    Memphis, Tennessee

  • GSK Investigational Site

    Arlington, Texas

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Corpus Christi, Texas

  • GSK Investigational Site

    Forney, Texas

  • GSK Investigational Site

    Houston, Texas

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.